Review
Copyright ©The Author(s) 2020.
World J Clin Cases. May 26, 2020; 8(10): 1767-1792
Published online May 26, 2020. doi: 10.12998/wjcc.v8.i10.1767
Table 4  In vivo hepatoprotective effects and related mechanisms of action of oleanolic acid and its natural and synthetic derivatives (2014-2020)
Disease model/ physiologyEffectMechanism
CompoundDoseiRef.
↑↑↑↓↓↓
Hepatic injury (mice, EtOH)Prevents ethanol induced liver injury, hepatoxicitynNRF-2, HO-1, SOD-1, CAT, GR, hepatic GSH, ATPsALT, sAST, CYP2E, ADH, TNF-α, IL-6, sTG, sLDHOA10 mg/kg·d, 30 d[60]
Hepatic injury (rats, CCl4)HepatoprotectiveSOD, GPXALT, AST, LDHOA, OA-Xs15 mg/kg[61]
Hepatic fibrosis (HSCs, HEPG2, BEL-7402, LO-2; mice, CCl4)HepatoprotectionApoptosis, Ca2+MitMP, sALT, sASTOA-amino acids20 mg/kg, IC50 > 50 µmol/L[62]
Hepatic fibrosis (rast, CCl4)Anti-hepatic fibrosis-sALT, sAST, Liver indicesOA-Xs14-28 mg/kg·3 d, 9 wk[63]
Hepatic injury (mice)HepatoprotectiveNQO1mKC, MIP-2, OATP-1B2, GADD-45, CHOP-10, sALT, sMDA, pJNK, HO-1.OA22.5 mg/kg·d, 3 d[64]
Cholestasis (HEPG2)Obstructive cholestasisurinary BA, MRP-3, MRP-4, MRP-2, NRF-2sBA, sBil, sAST, sALT, sALP, nNRF-2, BSEP,OA20 mg/kg, i.p, 1-50 µmol/L[65]
Cholestasis (mice, LCA)CholestasisMRP-2, MRP-3, MRP-4, NRF-2sALT, sALP, sAST, tBA, tBIL, SULT-2A1OA5-20 µg/kg[66]
Hepatic NAFLD (rats, HFD)Anti-NAFLD via AMPK-related pathwaysHGF, ICAM, IGF-1, IGFBP-3, IGFBP-5, IGFBP-6, lipocalin-2, MCP-1, M-CSF, PREF-1, RAGE, GLUT-2, LDLR, pAMPK, pAKT, pGSK-3β,TC, TG, LDL-COA-Xs60 mg/kg·d, 4 wk[67]
Hepatic IRI (mice)HO-1/Sesn2 signaling pathwayPI3K, HO-1, pAKTsAST, sALTOA30 mg/kg·d, 7 d[68]
Hepatic IRI (rat)Protects agaist hepatic IRIpPI3K, pAKT, pGSK-3βSALT, IL-1βOA100 mg/kg·d, 7 d before IRI[69]
Hepatic IRI, (mice)Alleviate hepatic IRIBCL-2apoptosis and autophagy, ALT, AST, CASP-3, CAPS-9, BAX, Beclin 1, LC3, TNF-α, HMG-B1, TLR-4, pJNKOA30-60 mg/kg, 7 d[70]